Nilaya Varma, Group CEO, Primus Partners, shares his view on India’s emerging position in the peptide drug manufacturing space. He highlights that while India is well-placed to tap into the growing global demand—especially with upcoming patent expiries like that of semaglutide—peptide manufacturing continues to face challenges. These include the availability of protected amino acids, coupling reagents, and the need for advanced purification processes for bulk APIs. Despite this, he notes the sector’s strong growth potential, backed by sustained investments in technology and capacity.